Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Molecular Partners ADR MOLN

Healthcare Biotechnology
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin... see more

Recent & Breaking News (NDAQ:MOLN)

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

GlobeNewswire 3 days ago

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

GlobeNewswire 5 days ago

Molecular Partners to Present at Upcoming Investor Conferences

GlobeNewswire May 19, 2025

Molecular Partners Reports Financial Results and Highlights from Q1 2025

GlobeNewswire May 15, 2025

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

GlobeNewswire April 25, 2025

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

GlobeNewswire April 16, 2025

Molecular Partners to hold three poster presentations at AACR 2025

GlobeNewswire March 25, 2025

Molecular Partners Publishes Invitation to Annual General Meeting 2025

GlobeNewswire March 25, 2025

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

GlobeNewswire March 6, 2025

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

GlobeNewswire February 28, 2025

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 12, 2025

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

GlobeNewswire January 12, 2025

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

GlobeNewswire December 17, 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

GlobeNewswire December 8, 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

GlobeNewswire November 7, 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

GlobeNewswire November 5, 2024

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

GlobeNewswire October 31, 2024

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

GlobeNewswire October 25, 2024

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

GlobeNewswire October 22, 2024

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

GlobeNewswire October 22, 2024